A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)

Trial Profile

A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Lanreotide (Primary) ; Yttrium-90 (Primary)
  • Indications Carcinoid tumour; Neuroendocrine carcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Apr 2017 Planned primary completion date changed from 1 Mar 2019 to 30 Apr 2019.
    • 06 Mar 2017 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
    • 06 Mar 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top